federal_register: 2016-02975

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2016-02975 Bioequivalence Recommendations for Cyclosporine; Draft Guidance for Industry; Availability Notice The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry on cyclosporine ophthalmic emulsion entitled "Draft Guidance on Cyclosporine." The recommendations provide specific guidance on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for cyclosporine ophthalmic emulsion. This draft guidance is a revised version of a previously issued draft guidance on the same subject. 2016-02-16 2016 2 https://www.federalregister.gov/documents/2016/02/16/2016-02975/bioequivalence-recommendations-for-cyclosporine-draft-guidance-for-industry-availability https://www.govinfo.gov/content/pkg/FR-2016-02-16/pdf/2016-02975.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry on cyclosporine ophthalmic emulsion entitled "Draft Guidance on Cyclosporine." The recommendations provide specific guidance on the design of...

Links from other tables